1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.

•HFD consumption alteres the expression of genes involved in lipid metabolism.•PGG reduces HFD-mediated body weight gain and hepatic steatosis.•PGG reverses HDF-induced alterations in hepatic lipid metabolic gene expression.•PGG, a well tolerated natural product, holds the potential for NAFLD treatment.